首页 > 最新文献

Procedia in vaccinology最新文献

英文 中文
The Application of a Proteoliposome Adjuvant System in the Development of a Campylobacter Jejuni Vaccine 蛋白脂质体佐剂体系在空肠弯曲杆菌疫苗研制中的应用
Pub Date : 2015-01-01 DOI: 10.1016/j.provac.2015.05.007
Barbara Rickaby , Nelson F. Eng , Annika Flint , Alain Stintzi , Francisco Diaz-Mitoma

The high incidence of Campylobacter jejuni-associated diarrhoea, the increase in the frequency of drug resistance, and the correlation between infection and Guillain-Barré syndrome, has heightened the need to develop effective anti-Campylobacter vaccines. Due to the risk of auto-immunity, vaccinations using whole-cells or attenuated cells are not clinical candidates. Subunit vaccines are viable alternatives and have been shown to be effective against other enteric pathogens. This research tested the efficacy of the catalase (KatA) from C. jejuni as a potential vaccine candidate against the pathogen. The protein was found to be immunogenic following an intramuscular murine immunization. A balanced IgG1/IgG2a response was generated when KatA was co-administered with monophosphoryl lipid A and alum. The antibodies elicited reduced the adhesion and invasion of C. jejuni to human epithelial cells (IECs) in vitro. The next phase of testing will be in combination with a proteoliposome (PL) derived from the outer membrane of V. cholerae. PL nano-vesicles were generated with an average size of ≈70 nm and had a zeta potential of ≈-40 mV.

肠弯曲杆菌相关腹泻的高发病率、耐药频率的增加以及感染与格林-巴-罗伊斯综合征之间的相关性,提高了开发有效的抗弯曲杆菌疫苗的必要性。由于自身免疫的风险,使用全细胞或减毒细胞接种疫苗不是临床候选。亚单位疫苗是可行的替代方案,并已被证明对其他肠道病原体有效。本研究测试了空肠梭菌过氧化氢酶(KatA)作为一种潜在的疫苗候选物的有效性。在小鼠肌内免疫后发现该蛋白具有免疫原性。当KatA与单磷酰脂质A和明矾共同给药时,产生平衡的IgG1/IgG2a反应。体外诱导的抗体可降低空肠梭菌对人上皮细胞的粘附和侵袭。下一阶段的测试将与从霍乱弧菌外膜提取的蛋白脂质体(PL)结合使用。生成的PL纳米囊泡平均尺寸约为70 nm, zeta电位约为-40 mV。
{"title":"The Application of a Proteoliposome Adjuvant System in the Development of a Campylobacter Jejuni Vaccine","authors":"Barbara Rickaby ,&nbsp;Nelson F. Eng ,&nbsp;Annika Flint ,&nbsp;Alain Stintzi ,&nbsp;Francisco Diaz-Mitoma","doi":"10.1016/j.provac.2015.05.007","DOIUrl":"10.1016/j.provac.2015.05.007","url":null,"abstract":"<div><p>The high incidence of <em>Campylobacter jejuni-</em>associated diarrhoea, the increase in the frequency of drug resistance, and the correlation between infection and Guillain-Barré syndrome, has heightened the need to develop effective anti-<em>Campylobacter</em> vaccines. Due to the risk of auto-immunity, vaccinations using whole-cells or attenuated cells are not clinical candidates. Subunit vaccines are viable alternatives and have been shown to be effective against other enteric pathogens. This research tested the efficacy of the catalase (KatA) from <em>C. jejuni</em> as a potential vaccine candidate against the pathogen. The protein was found to be immunogenic following an intramuscular murine immunization. A balanced IgG1/IgG2a response was generated when KatA was co-administered with monophosphoryl lipid A and alum. The antibodies elicited reduced the adhesion and invasion of <em>C. jejuni</em> to human epithelial cells (IECs) <em>in vitro</em>. The next phase of testing will be in combination with a proteoliposome (PL) derived from the outer membrane of <em>V. cholerae</em>. PL nano-vesicles were generated with an average size of ≈70<!--> <!-->nm and had a zeta potential of ≈-40<!--> <!-->mV.</p></div>","PeriodicalId":89221,"journal":{"name":"Procedia in vaccinology","volume":"9 ","pages":"Pages 38-43"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.provac.2015.05.007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54989899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Pertussis Booster Vaccination in Pregnancy: Women Who had it Compared to Those Who Waited 怀孕期间百日咳加强疫苗接种:与那些等待接种的妇女相比
Pub Date : 2015-01-01 DOI: 10.1016/j.provac.2015.05.010
E.H. Hayles , S.C. Cooper , N. Wood , S.R. Skinner , J.H.K. Sinn

Background

Guidelines for protecting young infants from pertussis now recommend maternal pertussis booster vaccination (dTpa) during pregnancy (3rd trimester) over postpartum maternal vaccination.

Methods

We undertook a cross-sectional survey of 723 postpartum women on the postnatal ward of a private hospital in Sydney, Australia. We excluded 47% of women who were ‘up to date’ with their pertussis booster prior to pregnancy. We surveyed the remaining 53% of women who were eligible for the pertussis booster vaccine during their pregnancy (no dTpa < 5years).

Results

In our study, pertussis booster vaccine uptake during pregnancy was only 8.7%. We confirmed that vaccination mostly occurred at the family doctor's practice (25/33; 75.8%), at an average of 34 weeks gestation (±5wks). Women vaccinated during pregnancy were more likely to report that they received a pregnancy-specific pertussis vaccine recommendation (<0.001), and had no vaccine safety concerns (0.004) or transport difficulties in accessing an immunization provider (0.032). They also had twice the odds of receiving an influenza vaccine during pregnancy (0.002). Additionally, 70% of vaccinated women reported that their partner had also been recently vaccinated against pertussis. Amongst unvaccinated women we found that 80% intended to be vaccinated, yet 33% would only do so if the vaccine was free (publically funded). Additionally, 40% of unvaccinated women would have agreed to pertussis vaccination during pregnancy had their doctor recommended it.

Conclusion

Providers should highlight pertussis vaccine safety and recommend vaccination during late pregnancy.

背景:保护幼儿免于百日咳的指南现在建议在怀孕期间(妊娠晚期)母亲接种百日咳加强疫苗(dTpa),而不是产后母亲接种疫苗。方法对澳大利亚悉尼一家私立医院产后病房的723名产后妇女进行横断面调查。我们排除了47%在怀孕前“及时”注射百日咳增强剂的妇女。我们调查了其余53%在怀孕期间有资格接种百日咳加强疫苗的妇女(没有dTpa <5年)。结果妊娠期百日咳加强疫苗接种率仅为8.7%。我们证实,疫苗接种主要发生在家庭医生的诊所(25/33;75.8%),平均妊娠34周(±5周)。在怀孕期间接种疫苗的妇女更有可能报告说,她们收到了针对妊娠的百日咳疫苗建议(<0.001),并且没有疫苗安全问题(0.004)或在获得免疫接种提供者时遇到交通困难(0.032)。她们在怀孕期间接种流感疫苗的几率也高出一倍(0.002)。此外,70%接种疫苗的妇女报告说,她们的伴侣最近也接种了百日咳疫苗。在未接种疫苗的妇女中,我们发现80%的人打算接种疫苗,但33%的人只有在疫苗免费(公共资助)的情况下才会这样做。此外,如果医生建议,40%未接种疫苗的妇女会同意在怀孕期间接种百日咳疫苗。结论应强调百日咳疫苗的安全性,并建议在妊娠后期接种。
{"title":"Pertussis Booster Vaccination in Pregnancy: Women Who had it Compared to Those Who Waited","authors":"E.H. Hayles ,&nbsp;S.C. Cooper ,&nbsp;N. Wood ,&nbsp;S.R. Skinner ,&nbsp;J.H.K. Sinn","doi":"10.1016/j.provac.2015.05.010","DOIUrl":"10.1016/j.provac.2015.05.010","url":null,"abstract":"<div><h3>Background</h3><p>Guidelines for protecting young infants from pertussis now recommend maternal pertussis booster vaccination (dTpa) during pregnancy (3<sup>rd</sup> trimester) over postpartum maternal vaccination.</p></div><div><h3>Methods</h3><p>We undertook a cross-sectional survey of 723 postpartum women on the postnatal ward of a private hospital in Sydney, Australia. We excluded 47% of women who were ‘up to date’ with their pertussis booster prior to pregnancy. We surveyed the remaining 53% of women who were eligible for the pertussis booster vaccine during their pregnancy (no dTpa<!--> <!-->&lt;<!--> <!-->5years).</p></div><div><h3>Results</h3><p>In our study, pertussis booster vaccine uptake during pregnancy was only 8.7%. We confirmed that vaccination mostly occurred at the family doctor's practice (25/33; 75.8%), at an average of 34 weeks gestation (±5wks). Women vaccinated during pregnancy were more likely to report that they received a pregnancy-specific pertussis vaccine recommendation (&lt;0.001), and had no vaccine safety concerns (0.004) or transport difficulties in accessing an immunization provider (0.032). They also had twice the odds of receiving an influenza vaccine during pregnancy (0.002). Additionally, 70% of vaccinated women reported that their partner had also been recently vaccinated against pertussis. Amongst unvaccinated women we found that 80% intended to be vaccinated, yet 33% would only do so if the vaccine was free (publically funded). Additionally, 40% of unvaccinated women would have agreed to pertussis vaccination during pregnancy had their doctor recommended it.</p></div><div><h3>Conclusion</h3><p>Providers should highlight pertussis vaccine safety and recommend vaccination during late pregnancy.</p></div>","PeriodicalId":89221,"journal":{"name":"Procedia in vaccinology","volume":"9 ","pages":"Pages 59-65"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.provac.2015.05.010","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54989921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
Haloarchaeal Gas Vesicle Nanoparticles Displaying Salmonella Antigens as a Novel Approach to Vaccine Development 显示沙门氏菌抗原的盐古菌气体囊泡纳米颗粒作为疫苗开发的新途径
Pub Date : 2015-01-01 DOI: 10.1016/j.provac.2015.05.003
P. DasSarma , V.D. Negi , A. Balakrishnan , J.-M. Kim , R. Karan , D. Chakravortty , S. DasSarma

A safe, effective, and inexpensive vaccine against typhoid and other Salmonella diseases is urgently needed. In order to address this need, we are developing a novel vaccine platform employing buoyant, self-adjuvanting gas vesicle nanoparticles (GVNPs) from the halophilic archaeon Halobacterium sp. NRC-1, bioengineered to display highly conserved Salmonella enterica antigens. As the initial antigen for testing, we selected SopB, a secreted inosine phosphate effector protein injected by pathogenic S. enterica bacteria during infection into the host cells. Two highly conserved sopB gene segments near the 3’- region, named sopB4 and sopB5, were each fused to the gvpC gene, and resulting SopB-GVNPs were purified by centrifugally accelerated flotation. Display of SopB4 and SopB5 antigenic epitopes on GVNPs was established by Western blotting analysis using antisera raised against short synthetic peptides of SopB. Immunostimulatory activities of the SopB4 and B5 nanoparticles were tested by intraperitoneal administration of SopB-GVNPs to BALB/c mice which had been immunized with S. enterica serovar Typhimurium 14028 ΔpmrG-HM-D (DV-STM-07), a live attenuated vaccine strain. Proinflammatory cytokines IFN-γ, IL-2, and IL-9 were significantly induced in mice boosted with SopB5-GVNPs, consistent with a robust Th1 response. After challenge with virulent S. enterica serovar Typhimurium 14028, bacterial burden was found to be diminished in spleen of mice boosted with SopB4-GVNPs and absent or significantly diminished in liver, mesenteric lymph node, and spleen of mice boosted with SopB5-GVNPs, indicating that the C-terminal portions of SopB displayed on GVNPs elicit a protective response to Salmonella infection in mice. SopB antigen-GVNPs were also found to be stable at elevated temperatures for extended periods without refrigeration. The results show that bioengineered GVNPs are likely to represent a valuable platform for antigen delivery and development of improved vaccines against Salmonella and other diseases.

目前迫切需要一种安全、有效和廉价的疫苗来预防伤寒和其他沙门氏菌疾病。为了满足这一需求,我们正在开发一种新的疫苗平台,利用来自嗜盐古菌盐杆菌NRC-1的浮力、自佐剂气体囊泡纳米颗粒(GVNPs),生物工程显示高度保守的肠沙门氏菌抗原。我们选择致病性肠链球菌在感染宿主细胞时通过注射分泌的磷酸肌苷效应蛋白SopB作为初始抗原。在3′-区附近的两个高度保守的sopB基因片段sopB4和sopB5分别与gvpC基因融合,得到的sopB - gvnps通过离心加速浮选纯化。利用合成SopB短肽的抗血清,通过Western blotting分析,在GVNPs上显示了SopB4和SopB5抗原表位。通过腹腔注射SopB-GVNPs,检测了SopB4和B5纳米颗粒对经肠炎沙门氏菌血清鼠伤寒杆菌14028 ΔpmrG-HM-D (DV-STM-07)减毒活疫苗株免疫的BALB/c小鼠的免疫刺激活性。促炎细胞因子IFN-γ、IL-2和IL-9在添加了SopB5-GVNPs的小鼠中被显著诱导,这与Th1的强烈反应一致。经强毒肠炎沙门氏菌血清型鼠伤寒杆菌14028攻毒后,经SopB4-GVNPs增强的小鼠脾脏细菌负荷减轻,而经SopB5-GVNPs增强的小鼠肝脏、肠系膜淋巴结和脾脏细菌负荷缺失或显著减少,表明GVNPs上显示的SopB c端部分引起小鼠对沙门氏菌感染的保护反应。SopB抗原- gvnps也被发现在高温下长时间不冷藏是稳定的。结果表明,生物工程GVNPs可能为抗原递送和开发针对沙门氏菌和其他疾病的改进疫苗提供了一个有价值的平台。
{"title":"Haloarchaeal Gas Vesicle Nanoparticles Displaying Salmonella Antigens as a Novel Approach to Vaccine Development","authors":"P. DasSarma ,&nbsp;V.D. Negi ,&nbsp;A. Balakrishnan ,&nbsp;J.-M. Kim ,&nbsp;R. Karan ,&nbsp;D. Chakravortty ,&nbsp;S. DasSarma","doi":"10.1016/j.provac.2015.05.003","DOIUrl":"10.1016/j.provac.2015.05.003","url":null,"abstract":"<div><p>A safe, effective, and inexpensive vaccine against typhoid and other <em>Salmonella</em> diseases is urgently needed. In order to address this need, we are developing a novel vaccine platform employing buoyant, self-adjuvanting gas vesicle nanoparticles (GVNPs) from the halophilic archaeon <em>Halobacterium</em> sp. NRC-1, bioengineered to display highly conserved <em>Salmonella enterica</em> antigens. As the initial antigen for testing, we selected SopB, a secreted inosine phosphate effector protein injected by pathogenic <em>S. enterica</em> bacteria during infection into the host cells. Two highly conserved <em>sopB</em> gene segments near the 3’- region, named <em>sop</em>B4 and <em>sop</em>B5, were each fused to the <em>gvpC</em> gene, and resulting SopB-GVNPs were purified by centrifugally accelerated flotation. Display of SopB4 and SopB5 antigenic epitopes on GVNPs was established by Western blotting analysis using antisera raised against short synthetic peptides of SopB. Immunostimulatory activities of the SopB4 and B5 nanoparticles were tested by intraperitoneal administration of SopB-GVNPs to BALB/c mice which had been immunized with <em>S. enterica</em> serovar Typhimurium 14028 Δ<em>pmrG-HM-D</em> (DV-STM-07), a live attenuated vaccine strain. Proinflammatory cytokines IFN-γ, IL-2, and IL-9 were significantly induced in mice boosted with SopB5-GVNPs, consistent with a robust Th1 response. After challenge with virulent <em>S. enterica</em> serovar Typhimurium 14028, bacterial burden was found to be diminished in spleen of mice boosted with SopB4-GVNPs and absent or significantly diminished in liver, mesenteric lymph node, and spleen of mice boosted with SopB5-GVNPs, indicating that the C-terminal portions of SopB displayed on GVNPs elicit a protective response to <em>Salmonella</em> infection in mice. SopB antigen-GVNPs were also found to be stable at elevated temperatures for extended periods without refrigeration. The results show that bioengineered GVNPs are likely to represent a valuable platform for antigen delivery and development of improved vaccines against <em>Salmonella</em> and other diseases.</p></div>","PeriodicalId":89221,"journal":{"name":"Procedia in vaccinology","volume":"9 ","pages":"Pages 16-23"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.provac.2015.05.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54989851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 15
Study of the Prevalence of Staphylococcus Aureus in Marine and Farmed Shrimps in Iran Aiming the Future Development of a Prophylactic Vaccine 伊朗海洋和养殖对虾中金黄色葡萄球菌流行率的研究,旨在开发预防性疫苗
Pub Date : 2015-01-01 DOI: 10.1016/j.provac.2015.05.008
N. Arfatahery, A. Mirshafiey, T.P. Abedimohtasab, M. Zeinolabedinizamani

Staphylococcus aureus is the most important pathogen found in sea foods. Food poisoning in human may happen due to the consumption of aqua products contaminated with this bacteria and its enterotoxin. The procedures carried out to maintain and preserve the quality of these products, from the time they are fished and transported to stores until they are consumed, can play a major role in the generation and growth of pathogenic bacteria and toxins. A total of 300 samples were collected, including (fresh and frozen, farm and marine). Consistent with the Iran National Standards, a number of phenotypical and molecular assays were utilized for screening S. aureus in order to detect Staphylococcus aureus. They study was conducted from September 2013 to March 2014. Baird Parker agar containing egg-yolk and tellurite emulsion were used for isolation. Isolates were identified using the following criteria: production of coagulase, DNase, catalase, mannitol fermentation, hemolytic zone on 5% sheep blood agar, VP test and Gramstaining A total of 74 samples (24.6%), were contaminated with Staphylococcus aureus. Due to the presence of Staphylococcus aureus in shrimps, it is necessary to enforce quality control standards by the fisheries and carefully monitor fishing, farming, preparation, freezing, and transporting marine products, and ensure the health of workers. The results of this study also showed it is necessary to produce and develop a vaccine to prevent the disease and sea-food poisoning caused by Staphylococcus aureus.

金黄色葡萄球菌是海产品中最重要的病原体。由于食用了被这种细菌及其肠道毒素污染的水产品,人类可能会发生食物中毒。为保持和保存这些产品的质量而进行的程序,从它们被捕捞和运输到商店,直到它们被消费,可能在致病菌和毒素的产生和生长中发挥重要作用。共收集了300个样本,包括(新鲜和冷冻,农场和海洋)。为了检测金黄色葡萄球菌,与伊朗国家标准一致,采用了许多表型和分子测定法筛选金黄色葡萄球菌。该研究于2013年9月至2014年3月进行。采用含蛋黄的Baird Parker琼脂和碲酸盐乳剂进行分离。采用凝固酶、脱氧核糖核酸酶、过氧化氢酶、甘露醇发酵、5%羊血琼脂溶血带、VP试验和革兰氏染色鉴定分离株,共74份(24.6%)样品被金黄色葡萄球菌污染。由于虾类中存在金黄色葡萄球菌,渔业部门有必要执行质量控制标准,对海产品的捕捞、养殖、制备、冷冻和运输进行严格监控,并确保工人的健康。研究结果还表明,有必要研制预防金黄色葡萄球菌引起的疾病和海鲜中毒的疫苗。
{"title":"Study of the Prevalence of Staphylococcus Aureus in Marine and Farmed Shrimps in Iran Aiming the Future Development of a Prophylactic Vaccine","authors":"N. Arfatahery,&nbsp;A. Mirshafiey,&nbsp;T.P. Abedimohtasab,&nbsp;M. Zeinolabedinizamani","doi":"10.1016/j.provac.2015.05.008","DOIUrl":"10.1016/j.provac.2015.05.008","url":null,"abstract":"<div><p><em>Staphylococcus aureus</em> is the most important pathogen found in sea foods. Food poisoning in human may happen due to the consumption of aqua products contaminated with this bacteria and its enterotoxin. The procedures carried out to maintain and preserve the quality of these products, from the time they are fished and transported to stores until they are consumed, can play a major role in the generation and growth of pathogenic bacteria and toxins. A total of 300 samples were collected, including (fresh and frozen, farm and marine). Consistent with the Iran National Standards, a number of phenotypical and molecular assays were utilized for screening <em>S. aureus</em> in order to detect <em>Staphylococcus aureus.</em> They study was conducted from September 2013 to March 2014. Baird Parker agar containing egg-yolk and tellurite emulsion were used for isolation. Isolates were identified using the following criteria: production of coagulase, DNase, catalase, mannitol fermentation, hemolytic zone on 5% sheep blood agar, VP test and Gramstaining A total of 74 samples (24.6%), were contaminated with <em>Staphylococcus aureus</em>. Due to the presence of <em>Staphylococcus aureus</em> in shrimps, it is necessary to enforce quality control standards by the fisheries and carefully monitor fishing, farming, preparation, freezing, and transporting marine products, and ensure the health of workers. The results of this study also showed it is necessary to produce and develop a vaccine to prevent the disease and sea-food poisoning caused by <em>Staphylococcus aureus</em>.</p></div>","PeriodicalId":89221,"journal":{"name":"Procedia in vaccinology","volume":"9 ","pages":"Pages 44-49"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.provac.2015.05.008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54989910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 18
Vaccine Refrigerator Regulator with Data Logger & Back-up Power Supply 疫苗冰箱调节器与数据记录器和备用电源
Pub Date : 2014-01-01 DOI: 10.1016/j.provac.2014.07.014
Andres Martin-de-Nicolas , Patrick McColloster MD

Introduction

Many vaccines require a storage temperature between 2-8 °C throughout thesupply cold chain. Multiple studies conducted at healthcare facilities worldwide document an endemicfailure to properly store vaccines, risking the efficacy of local vaccination programs.This “weak link” at the end of the cold chainis largely due to both the widespread use of inadequate domestic refrigerators for vaccine storage, and electrical power interruptions. The required specialized refrigeration equipment and backup power systemareboth prohibitively expensive for smaller facilities. Prompted by this finding, the authors sought an affordable solution for small-scale vaccine storage applications.

Methods

The solution presented is an aftermarketappliance designed toaccompany a wide range of domestic refrigerators.After undergoing an initial calibration step, the device effectively overridesthe refrigerator's native thermostat(s) and assumes thermoregulatory control. All interfaces between the device and the refrigerator are strictly external, allowing for installation by a layperson. Wireless temperature sensor measurements are frequently logged to a removable USB thumb drive to provide vaccine temperature traceability. The device is further equipped to charge an external battery while grid power is available, and upon grid failure automatically source refrigeration power froman attached external inverter.

Results

The regulator device successfullymaintained a 2-8 °C environment for all properly stored vaccine vials. Furthermore, it successfully adapted to and compensated for the individual operational characteristics of various refrigerators, and flagged those unsuitable for vaccine storage. Back-up power outage resiliency is recorded at16-25 hours for 18-28ft3sized household refrigerators using a 160Ah battery.The cost of manufacturing the device is estimated at $250 per unit.

Discussion

The Baylor/Rice regulator device provides an affordable refrigeration control and temperature monitoring system suitable for converting household refrigerators into effective vaccine refrigerators. The device will also be useful in areas subject to electrical grid failure.

许多疫苗在整个供应冷链中需要2-8°C的储存温度。在世界各地的卫生保健机构进行的多项研究记录了一种地方性的未能妥善储存疫苗的现象,危及当地疫苗接种计划的效力。这一冷链末端的“薄弱环节”主要是由于广泛使用不充分的家用冰箱来储存疫苗,以及电力中断。所需的专门制冷设备和备用电源系统对于较小的设施来说都过于昂贵。在这一发现的推动下,作者为小规模疫苗储存应用寻找了一种负担得起的解决方案。方法提出的解决方案是一种售后设备,设计用于各种家用冰箱。经过初始校准步骤后,该设备有效地覆盖了冰箱的本机恒温器,并承担温度调节控制。设备和冰箱之间的所有接口都是严格外部的,允许外行人安装。无线温度传感器测量经常记录到一个可移动的USB拇指驱动器,以提供疫苗温度可追溯性。该装置还可以在电网供电时对外部电池充电,并在电网故障时自动从附加的外部逆变器获取制冷电源。结果该调节装置成功地维持了2-8°C的环境,所有疫苗瓶都被妥善保存。此外,它成功地适应和补偿了各种冰箱的个别操作特性,并标记了不适合储存疫苗的冰箱。使用160Ah电池的18-28ft3大小的家用冰箱的备用停电弹性记录为16-25小时。制造这种设备的成本估计为每台250美元。Baylor/Rice调节装置提供了一种经济实惠的制冷控制和温度监测系统,适用于将家用冰箱转换为有效的疫苗冰箱。该装置在电网故障地区也很有用。
{"title":"Vaccine Refrigerator Regulator with Data Logger & Back-up Power Supply","authors":"Andres Martin-de-Nicolas ,&nbsp;Patrick McColloster MD","doi":"10.1016/j.provac.2014.07.014","DOIUrl":"10.1016/j.provac.2014.07.014","url":null,"abstract":"<div><h3>Introduction</h3><p>Many vaccines require a storage temperature between 2-8<!--> <!-->°C throughout thesupply cold chain. Multiple studies conducted at healthcare facilities worldwide document an endemicfailure to properly store vaccines, risking the efficacy of local vaccination programs.This “weak link” at the end of the cold chainis largely due to both the widespread use of inadequate domestic refrigerators for vaccine storage, and electrical power interruptions. The required specialized refrigeration equipment and backup power systemareboth prohibitively expensive for smaller facilities. Prompted by this finding, the authors sought an affordable solution for small-scale vaccine storage applications.</p></div><div><h3>Methods</h3><p>The solution presented is an aftermarketappliance designed toaccompany a wide range of domestic refrigerators.After undergoing an initial calibration step, the device effectively overridesthe refrigerator's native thermostat(s) and assumes thermoregulatory control. All interfaces between the device and the refrigerator are strictly external, allowing for installation by a layperson. Wireless temperature sensor measurements are frequently logged to a removable USB thumb drive to provide vaccine temperature traceability. The device is further equipped to charge an external battery while grid power is available, and upon grid failure automatically source refrigeration power froman attached external inverter.</p></div><div><h3>Results</h3><p>The regulator device successfullymaintained a 2-8<!--> <!-->°C environment for all properly stored vaccine vials. Furthermore, it successfully adapted to and compensated for the individual operational characteristics of various refrigerators, and flagged those unsuitable for vaccine storage. Back-up power outage resiliency is recorded at16-25<!--> <!-->hours for 18-28ft<sup>3</sup>sized household refrigerators using a 160Ah battery.The cost of manufacturing the device is estimated at $250 per unit.</p></div><div><h3>Discussion</h3><p>The Baylor/Rice regulator device provides an affordable refrigeration control and temperature monitoring system suitable for converting household refrigerators into effective vaccine refrigerators. The device will also be useful in areas subject to electrical grid failure.</p></div>","PeriodicalId":89221,"journal":{"name":"Procedia in vaccinology","volume":"8 ","pages":"Pages 89-93"},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.provac.2014.07.014","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54989817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Protective Properties of Inactivated Virosomal Influenza Vaccine 灭活病毒体流感疫苗的保护特性
Pub Date : 2014-01-01 DOI: 10.1016/j.provac.2014.07.005
М.К. Erofeeva , I.J. Nickonorov , V.L. Maksakova , M.A. Stukova , O.S. Konshina , E.A. Okhapkina , E.M. Voicehovskaya , S.A. Korovkin , S.J. Melnikhov , O.I. Kiselev

Currently, application of new technological solutions for the implementation of strategies for improving influenza vaccines are up to date and modern. In this study, we present data obtained in the evaluation of the safety and immunogenicity of the new Russian (national) split seasonal inactivated influenza vaccine ULTRIKS in comparison with a commercial vaccine VAXIGRIP in various age groups.

目前,应用新技术解决方案来实施改进流感疫苗的战略是最新的和现代的。在这项研究中,我们介绍了俄罗斯(国家)新分离季节性灭活疫苗ULTRIKS与商业疫苗VAXIGRIP在不同年龄组中的安全性和免疫原性评估数据。
{"title":"Protective Properties of Inactivated Virosomal Influenza Vaccine","authors":"М.К. Erofeeva ,&nbsp;I.J. Nickonorov ,&nbsp;V.L. Maksakova ,&nbsp;M.A. Stukova ,&nbsp;O.S. Konshina ,&nbsp;E.A. Okhapkina ,&nbsp;E.M. Voicehovskaya ,&nbsp;S.A. Korovkin ,&nbsp;S.J. Melnikhov ,&nbsp;O.I. Kiselev","doi":"10.1016/j.provac.2014.07.005","DOIUrl":"10.1016/j.provac.2014.07.005","url":null,"abstract":"<div><p>Currently, application of new technological solutions for the implementation of strategies for improving influenza vaccines are up to date and modern. In this study, we present data obtained in the evaluation of the safety and immunogenicity of the new Russian (national) split seasonal inactivated influenza vaccine ULTRIKS in comparison with a commercial vaccine VAXIGRIP in various age groups.</p></div>","PeriodicalId":89221,"journal":{"name":"Procedia in vaccinology","volume":"8 ","pages":"Pages 24-33"},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.provac.2014.07.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54990213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Vaccine Development for Prescottella Equi 马Prescottella的疫苗研制
Pub Date : 2014-01-01 DOI: 10.1016/j.provac.2014.07.009
T. Vanniasinkam , C. Giles , S. Ndi , M. Heuzenroeder , M. Barton

Prescottella equi (formerly Rhodococcus equi) is an intracellular pathogen that causes pyogranulomatous pneumonia in Thoroughbred foals. There is currently no vaccine available for the prevention of this disease in foals despite years of research. Cell mediated immunity is considered crucial for overcoming an infection caused by this pathogen. The virulence associated protein (VapA) is a well characterized immunogenic protein associated with this pathogen and was used to develop DNA and recombinant protein vaccines in this study. Vaccine candidates and live P. equi based vaccine were tested in BALB/c mice. Mice were challenged with virulent P.equi 2 weeks following the last boost and IgG subtypes and bacterial clearance from spleen and liver determined. The DNA vaccine elicited a significant IgG2a response indicating a Th1 biased immune response. The IFN gamma response from DNA and recombinant VapA vaccinated mice was moderate. The results of the challenge study showed that neither the recombinant VapA protein nor DNA vaccine enhanced clearance of P. equi in this model.

马Prescottella(原马红球菌)是一种细胞内病原体,可引起纯种马驹脓肉芽肿性肺炎。尽管经过多年的研究,目前还没有预防马驹这种疾病的疫苗。细胞介导免疫被认为是克服由这种病原体引起的感染的关键。毒力相关蛋白(vir毒力相关蛋白,VapA)是一种特性良好的与该病原体相关的免疫原性蛋白,在本研究中被用于开发DNA和重组蛋白疫苗。在BALB/c小鼠身上试验了候选疫苗和马弓形虫活疫苗。在最后一次增强后2周,用毒力强的马棘球蚴攻击小鼠,测定脾脏和肝脏的IgG亚型和细菌清除率。DNA疫苗引起了显著的IgG2a应答,表明Th1偏向性免疫应答。DNA和重组VapA疫苗小鼠的IFN γ反应是中等的。攻毒研究结果表明,重组VapA蛋白和DNA疫苗均不能提高该模型对马链球菌的清除率。
{"title":"Vaccine Development for Prescottella Equi","authors":"T. Vanniasinkam ,&nbsp;C. Giles ,&nbsp;S. Ndi ,&nbsp;M. Heuzenroeder ,&nbsp;M. Barton","doi":"10.1016/j.provac.2014.07.009","DOIUrl":"10.1016/j.provac.2014.07.009","url":null,"abstract":"<div><p><em>Prescottella equi</em> (formerly <em>Rhodococcus equi</em>) is an intracellular pathogen that causes pyogranulomatous pneumonia in Thoroughbred foals. There is currently no vaccine available for the prevention of this disease in foals despite years of research. Cell mediated immunity is considered crucial for overcoming an infection caused by this pathogen. The virulence associated protein (VapA) is a well characterized immunogenic protein associated with this pathogen and was used to develop DNA and recombinant protein vaccines in this study. Vaccine candidates and live <em>P. equi</em> based vaccine were tested in BALB/c mice. Mice were challenged with virulent <em>P.equi</em> 2 weeks following the last boost and IgG subtypes and bacterial clearance from spleen and liver determined. The DNA vaccine elicited a significant IgG2a response indicating a Th1 biased immune response. The IFN gamma response from DNA and recombinant VapA vaccinated mice was moderate. The results of the challenge study showed that neither the recombinant VapA protein nor DNA vaccine enhanced clearance of <em>P. equi</em> in this model.</p></div>","PeriodicalId":89221,"journal":{"name":"Procedia in vaccinology","volume":"8 ","pages":"Pages 50-57"},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.provac.2014.07.009","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54990256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
On the Use of the Concept of “Fairness” in the World of Vaccines and Vaccination 论“公平”概念在疫苗和疫苗接种领域的运用
Pub Date : 2014-01-01 DOI: 10.1016/j.provac.2014.07.002
Raymond E. Spier

The concept of “fairness” is introduced and its position in the ethical systems of rights and virtues outlined. The application of such thinkings to the worlds of vaccines and vaccination is then examined in some detail. This domain stretches from the inception of the idea of a need for a prophylactic measure to counter a historic or modern disease, beit caused by an infectious or a non-infectious agent. At each stage of this process a view is taken as to the issues that arise from fair or unfair behaviours. This leads to conclusions that focus on the way we regulate the issuance of a licence to manufacture and sell a vaccine in addition to the emphasising the need to focus on immunogens that are both universal and cross-protective with regard to their being able to counter the disease causing properties of pathogens that can “change their outer surfaces”. A concluding look at the ethical principles that are engendered in this paper highlights the need to accept responsibilities to seek to improve the well-being of our societies both in kind and by adopting attitudes and behaviours that give a reality to the notions of the virtues of fairness and justice that is the theme of this work.

介绍了“公平”的概念,概述了“公平”在权利伦理体系和美德伦理体系中的地位。这些思想在疫苗和疫苗接种领域的应用,然后进行了一些详细的研究。这一领域从一开始就有必要采取预防措施,以对付由传染性或非传染性病原体引起的历史或现代疾病。在这一过程的每个阶段,对公平或不公平行为所产生的问题采取一种看法。由此得出的结论是,除了强调需要关注具有普适性和交叉保护性的免疫原,因为它们能够对抗可"改变其外表面"的病原体的致病特性外,重点关注我们如何管理疫苗生产和销售许可证的发放。最后,对本文中产生的伦理原则进行了总结,强调需要承担责任,以实物和采取态度和行为来寻求改善我们社会的福祉,这些态度和行为使公平和正义的美德概念成为现实,这是本工作的主题。
{"title":"On the Use of the Concept of “Fairness” in the World of Vaccines and Vaccination","authors":"Raymond E. Spier","doi":"10.1016/j.provac.2014.07.002","DOIUrl":"10.1016/j.provac.2014.07.002","url":null,"abstract":"<div><p>The concept of “fairness” is introduced and its position in the ethical systems of rights and virtues outlined. The application of such thinkings to the worlds of vaccines and vaccination is then examined in some detail. This domain stretches from the inception of the idea of a need for a prophylactic measure to counter a historic or modern disease, beit caused by an infectious or a non-infectious agent. At each stage of this process a view is taken as to the issues that arise from fair or unfair behaviours. This leads to conclusions that focus on the way we regulate the issuance of a licence to manufacture and sell a vaccine in addition to the emphasising the need to focus on immunogens that are both universal and cross-protective with regard to their being able to counter the disease causing properties of pathogens that can “change their outer surfaces”. A concluding look at the ethical principles that are engendered in this paper highlights the need to accept responsibilities to seek to improve the well-being of our societies both in kind and by adopting attitudes and behaviours that give a reality to the notions of the virtues of fairness and justice that is the theme of this work.</p></div>","PeriodicalId":89221,"journal":{"name":"Procedia in vaccinology","volume":"8 ","pages":"Pages 5-11"},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.provac.2014.07.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54990173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Primary Cervical Cancer Prevention in Morocco: HPV Vaccine Awareness and Acceptability among Parents 摩洛哥原发性宫颈癌预防:HPV疫苗在父母中的认识和接受程度
Pub Date : 2014-01-01 DOI: 10.1016/j.provac.2014.07.012
M. Mouallif , H. Bowyer , S. Festali , A. Albert , Y. Filali , S. Guenin , P. Delvenne , J. Waller , M. Ennaji

Cervical cancer is a major public health concern in Morocco where it represents the second most common and lethal cancer in women. Human papillomavirus (HPV) vaccines have been licensed in Morocco since 2008 but there is no available data on their acceptability. This study aimed to assess awareness of HPV and the vaccine, and to identify factors associated with acceptability of the vaccine among parents in Morocco. A questionnaire-based survey using face-to-face interviews was conducted in a sample of 852 parents (670 mothers and 182 fathers) with at least one unmarried daughter ≤26 years. The study took place within public and private health centres and clinics in four regions in Morocco between July and August 2012. The main outcome measure was willingness to consider vaccinating a daughter against HPV. Responses revealed very low awareness of HPV infection (5%) and the HPV vaccine (14%). None of the participants had vaccinated their daughters against HPV and only 35% (32% of mothers and 45% of fathers) were willing to consider doing so in the future. Higher education and income, previous awareness of the HPV vaccine and endorsement of the belief that a recommendation from the ministry of health or a doctor to have the vaccine would be encouraging, were associated with mothers’ HPV vaccine acceptance. Non-acceptance among mothers was associated with having more than two daughters, believing the vaccine was expensive and lack of information. The only factor associated with the fathers’ acceptance of the vaccine was the cost. Increasing HPV and HPV vaccine awareness through educational campaigns, along with active recommendation by physicians and a publically funded vaccination programme could increase parental acceptance of the vaccine in Morocco.

宫颈癌是摩洛哥的一个主要公共卫生问题,是摩洛哥妇女中第二大常见和致命的癌症。人乳头瘤病毒(HPV)疫苗自2008年以来已在摩洛哥获得许可,但没有关于其可接受性的现有数据。这项研究的目的是评估对HPV和疫苗的认识,并确定与摩洛哥父母接受疫苗有关的因素。采用面对面访谈的问卷调查方式,对852名父母(670名母亲和182名父亲)进行了调查,这些父母至少有一个未婚女儿≤26岁。这项研究于2012年7月至8月期间在摩洛哥四个地区的公共和私人保健中心和诊所进行。主要结果测量是考虑给女儿接种HPV疫苗的意愿。应答显示对HPV感染(5%)和HPV疫苗(14%)的认识非常低。没有一个参与者给他们的女儿接种过HPV疫苗,只有35%的人(32%的母亲和45%的父亲)愿意考虑在未来这样做。高等教育和收入、以前对人乳头瘤病毒疫苗的认识以及相信卫生部或医生建议接种疫苗会令人鼓舞,这些都与母亲接受人乳头瘤病毒疫苗有关。母亲不接受疫苗接种与她们有两个以上女儿有关,她们认为疫苗很贵,而且缺乏相关信息。父亲们接受疫苗的唯一因素是费用。通过教育运动提高人乳头瘤病毒和人乳头瘤病毒疫苗的认识,加上医生的积极建议和公共资助的疫苗接种规划,可以提高摩洛哥父母对疫苗的接受程度。
{"title":"Primary Cervical Cancer Prevention in Morocco: HPV Vaccine Awareness and Acceptability among Parents","authors":"M. Mouallif ,&nbsp;H. Bowyer ,&nbsp;S. Festali ,&nbsp;A. Albert ,&nbsp;Y. Filali ,&nbsp;S. Guenin ,&nbsp;P. Delvenne ,&nbsp;J. Waller ,&nbsp;M. Ennaji","doi":"10.1016/j.provac.2014.07.012","DOIUrl":"10.1016/j.provac.2014.07.012","url":null,"abstract":"<div><p>Cervical cancer is a major public health concern in Morocco where it represents the second most common and lethal cancer in women. Human papillomavirus (HPV) vaccines have been licensed in Morocco since 2008 but there is no available data on their acceptability. This study aimed to assess awareness of HPV and the vaccine, and to identify factors associated with acceptability of the vaccine among parents in Morocco. A questionnaire-based survey using face-to-face interviews was conducted in a sample of 852 parents (670 mothers and 182 fathers) with at least one unmarried daughter ≤26 years. The study took place within public and private health centres and clinics in four regions in Morocco between July and August 2012. The main outcome measure was willingness to consider vaccinating a daughter against HPV. Responses revealed very low awareness of HPV infection (5%) and the HPV vaccine (14%). None of the participants had vaccinated their daughters against HPV and only 35% (32% of mothers and 45% of fathers) were willing to consider doing so in the future. Higher education and income, previous awareness of the HPV vaccine and endorsement of the belief that a recommendation from the ministry of health or a doctor to have the vaccine would be encouraging, were associated with mothers’ HPV vaccine acceptance. Non-acceptance among mothers was associated with having more than two daughters, believing the vaccine was expensive and lack of information. The only factor associated with the fathers’ acceptance of the vaccine was the cost. Increasing HPV and HPV vaccine awareness through educational campaigns, along with active recommendation by physicians and a publically funded vaccination programme could increase parental acceptance of the vaccine in Morocco.</p></div>","PeriodicalId":89221,"journal":{"name":"Procedia in vaccinology","volume":"8 ","pages":"Pages 68-76"},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.provac.2014.07.012","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54990293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Evaluation of a Burkholderia Pseudomallei Outer Membrane Vesicle Vaccine in Nonhuman Primates 假性伯克氏菌外膜囊泡疫苗在非人灵长类动物中的评价
Pub Date : 2014-01-01 DOI: 10.1016/j.provac.2014.07.007
Hailey Petersen , Wildaliz Nieves , Kasi Russell-Lodrigue , Chad J. Roy , Lisa A. Morici

Burkholderia pseudomallei (Bps)is the causative agent of melioidosis and is endemic in regions of northern Australia and Southeast Asia. Bps is inherently resistant to multiple antibiotics and is considered a potential biological warfare agent by the U.S. DHHS. Therefore, effective vaccines are necessary to prevent natural infection and to safeguard against biological attack with this organism. In our previous work we have shown that immunization with naturally derived outer membrane vesicles (OMVs) from Bps provides significant protection against lethal aerosol and systemic infection in BALB/c mice. In this work, we evaluated the safety and immunogenicity of escalating doses of OMV vaccine in rhesus macaques. We show that immunization of rhesus macaques with Bps OMVs generates humoral immuneresponses to protective protein and polysaccharide antigens without any associated toxicity or reactogenicity. These results lay the groundwork for evaluation of protective efficacy of the OMV vaccine in the nonhuman primate model of melioidosis.

假性伯克霍尔德菌(Bps)是类鼻疽病的病原体,在澳大利亚北部和东南亚地区流行。Bps本身对多种抗生素具有耐药性,被美国国土安全部认为是一种潜在的生物战剂。因此,有效的疫苗是必要的,以防止自然感染和保护免受生物攻击的有机体。在我们之前的工作中,我们已经证明,用Bps天然衍生的外膜囊泡(OMVs)免疫BALB/c小鼠,可以显著保护小鼠免受致命气溶胶和全身感染。在这项工作中,我们在恒河猴中评估了递增剂量的OMV疫苗的安全性和免疫原性。我们发现,用Bps omv免疫恒河猴可产生对保护蛋白和多糖抗原的体液免疫反应,而没有任何相关的毒性或反应原性。这些结果为评估OMV疫苗在类鼻虫病非人灵长类动物模型中的保护效果奠定了基础。
{"title":"Evaluation of a Burkholderia Pseudomallei Outer Membrane Vesicle Vaccine in Nonhuman Primates","authors":"Hailey Petersen ,&nbsp;Wildaliz Nieves ,&nbsp;Kasi Russell-Lodrigue ,&nbsp;Chad J. Roy ,&nbsp;Lisa A. Morici","doi":"10.1016/j.provac.2014.07.007","DOIUrl":"10.1016/j.provac.2014.07.007","url":null,"abstract":"<div><p><em>Burkholderia pseudomallei</em> (<em>Bps</em>)is the causative agent of melioidosis and is endemic in regions of northern Australia and Southeast Asia. <em>Bps</em> is inherently resistant to multiple antibiotics and is considered a potential biological warfare agent by the U.S. DHHS. Therefore, effective vaccines are necessary to prevent natural infection and to safeguard against biological attack with this organism. In our previous work we have shown that immunization with naturally derived outer membrane vesicles (OMVs) from <em>Bps</em> provides significant protection against lethal aerosol and systemic infection in BALB/c mice. In this work, we evaluated the safety and immunogenicity of escalating doses of OMV vaccine in rhesus macaques. We show that immunization of rhesus macaques with <em>Bps</em> OMVs generates humoral immuneresponses to protective protein and polysaccharide antigens without any associated toxicity or reactogenicity. These results lay the groundwork for evaluation of protective efficacy of the OMV vaccine in the nonhuman primate model of melioidosis.</p></div>","PeriodicalId":89221,"journal":{"name":"Procedia in vaccinology","volume":"8 ","pages":"Pages 38-42"},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.provac.2014.07.007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32621102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 39
期刊
Procedia in vaccinology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1